Skip to main content

Table 3 HPV prevalence detected by Cervista and HC2 in comparison to LBC

From: A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off

LBC CER+ve (%) HR HC2+ve (%) κ (95% CI)
Normal (Pap I/II) 10.8% 5.7% 0.53 (0.43-0.61)
ASC-US (Pap IIw) 30.8% 27.7% 0.55 (0.33-0.78)
ASC-H, AGUS (Pap III) 50.0% 45.0% 0.9 (0.71-1.0)
LSIL, HSIL (Pap IIID) 67.2% 71.5% 0.82 (0.75-0.88)
HSIL, CIS (Pap IVa) 97.2% 100 % 1
HSIL, CIS, Micro (IVb) 100% 100% 1
Microinvasive (Pap V) 100% 100% 1
AGUS+ (≥Pap III) 71.3% 75.2% 0.83 (0.77-0.88)
HSIL+ (≥Pap IVa) 100% 100% 1
Total 27.8% 25.2% 0.8 (0.77-0.84)
  1. +ve: positive; +: and higher.
  2. 95% CI for HPV prevalence were calculated using the Wilson Score method.